Abstract
The oral cytostatic activity in L1210 mouse leukaemia of the two newN 4-alkyl derivatives of 1-β-d-arabinofuranosylcytosine (AraC),N 4-hexadecyl- andN 4-octadecyl-1-β-d-arabinofuranosylcytosine (NH- AraC, NO-AraC) was investigated. In contrast to AraC, both derivatives were highly cytostatic after oral application as liposome formulations. With treatment schedules of five consecutive dosages or with two applications on days 1 and 4 after intravenous tumour cell inoculation with a total dose of 470–1000 mg/kg NH- AraC or NO-AraC, 70%–100% of the treated animals were cured. The lethal dose in healthy ICR mice after a single intraperitoneal application, corresponding to the LD50, was 524 mg/kg for NO-AraC, whereas NH- AraC proved to be less toxic. The haematological toxicity. remained moderate for both drugs with a mild leucopenia and a drop in platelet counts, which recovered 4–6 days after treatment. The erythrocytes were not affected and haemolytic toxicities were absent. As non-haematological toxicities, at high drug concentrations, a pronounced atrophy of the rapidly dividing epithelia of the small intestines and of the white pulp of the spleen were observed. The blood levels of NH-AraC given orally reached values comparable to those after parenteral application of a four-times lower dose of NH-AraC, suggesting a moderate bioavailability. Thus, these two lipophilic derivatives of AraC are compounds with a potential for the oral treatment of malignant diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- NH-AraC :
-
N 4-hexadecyl-1-β-d-arabino-furanosylcytosine
- NO-AraC :
-
N 4-octadecyl-1-β-d-arabinofuranosylcytosine
- AraC :
-
1-β-d-arabinofuranosylcytosine
References
Allen TM (1989) Stealth-liposomes: avoiding reticuloendothelial uptake. In: Lopez-Berenstein G, Fidler IJ (eds) Liposomes in the therapy of infectious diseases and cancer. Liss, New York, pp 405–415
Braess, J, Ramsauer B, Hiddemann W, Burk K, Schüssler M, Keye S, Schleyer E (1994) Pharmacokinetics of YNK01 (fosteabine)-the oral derivative of cytosinearabinoside. Ann Oncol S5:173
Chabner BA (1990) Cytidine analogues. In: Chabner BA, Collins JM (eds) Cancer chemotherapy, principles and practice. Lippincott, Philadelphia, pp 154–179
Hellström-Lindberg E, Robert KH, Gahrton G, Lindberg G, Forsblom AM, Kock Y, Ost A (1994) Low-dose ara-C in myelodysplastic syndromes (MSD) and acute leukaemia following MSD: proposal for a predictive model. Leuk Lymphoma 12:343–351
Heuvel MJ van den, Clark DG, Fielder RJ, Koundakarjian PP, Oliver GJ, Pelling D, Tomlison NJ, Walker AP (1990) The international validation of a fixed-dose procedure as an alternative to the classical LD50 test. Food Chem Toxicol 28:469–482
Ho DHW, Frei E (1971) Clinical pharmacology of 1-β-D-arabino-furanosylcytosine. Clin Pharmacol Ther 12:944–954
Ho DH, Carter CJ, Loo TL, Abbott RL, McBride CM (1975) Pharmacologic studies of cyclocytidine and arabinosylcytosine in dogs. Drug Metab Dispos 3:309–313
Hope MJ, Bally MB, Webb G, Cullis PR (1985) Production of large unilamellar vesicles by a rapid procedure, characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 812:55–65
Horber DH, Schott H, Schwendener RA (1995a) Pharmacokinetic properties and interactions with blood components ofN 4-hexadecyl-1-β-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. J Pharm Pharmacol 47:282–288
Horber DH, Schott H, Schwendener RA (1995b) Cellular pharmacology of a liposomal preparation ofN 4-hexadecyl-1-β-D-arabinofuranosylcytosine a lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer 71:957–962
Horber DH, Ballmoos P von, Schott H, Schwendener RA (1995c) Cell cycle dependent cytotoxicity and induction of apoptosis byN 4-hexadecyl-1-β-D-arabinofuranosyl-cytosine, a new lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer (in press)
Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ (1992) Evolution of treatment for acute myelogenous leukaemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985–1991. Leukaemia 6[Suppl 2]: 78–80
Kodama K, Morozumi M, Saitoh K, Kuninaka A, Yoshino H, Saneyoshi M (1989) Antitumor activity and pharmacology of 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate: an orally active derivative of 1-β-D-arabinofuranosylcytosine. Jpn J Cancer Res 80:679–685
Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, Cassileth PA, O'Connell MJ, Kyungmann K (1992) The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase III study. Ann Haematol 65:162–168
Neil GL, Moxley TE, Manak RC (1970) Enhancement by tetrahydrouridine of 1-β-D-arabinofuranosylcytosine (Cytarabine) oral acivity in L1210 leukemic mice. Cancer Res 30:2166–2172
Ohno R, Hirano M, Yamagata K, Ohara K, Shirakawa S, Hirota, Kobayashi M, Yoshikawa S, Mitomo Y, Ikeda Y, Tokai blood Cancer Study Group (1986) Treatment of leukaemia and myelodysplastic syndromes with orally administeredN 4-palmitoyl-1-β-D-arabinofuranosylcytosine. Cancer Chemother Pharmacol 17:161–164
Ohno R, Tatsumi N, Hirano M, Imai K, Mizoguchi H, Nakamura T, Kosaka M et al. (1991) Treatment of myelodysplastic syndromes with orally administred 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate. Oncology 48:451–455
Rosowsky A, Kim SH, Ross J, Wick MM (1982) Lipophilic 5′-(alkyl phosphate) esters of 1-β-D-arabinofuranosylcytosine and itsN 4-acyl and 2,2′-anhydro-3′-O-acylderivatinves as potential prodrugs. J Med Chem 25:171–178
Rubas W, Supersaxo A, Weder HG, Hartmann HR, Hengartner H, Schott H, Schwendener RA (1986) Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer 37:149–154
Schott H, Häussler MP, Schwendener RA (1994) Synthese von 4-Alkylcytosinnucleosiden und deren cytostatische Widkung im L1210 Läukemiemodell der Maus. Liebigs Ann Chem 465
Schwendener RA, Schott H (1992) Treatment of L1210 murine leukemia with liposome-incorporatedN 4-hexadecyl-1-β-D-arabinofuranosylcytosine. Int J Cancer 52:1–4
Schwendener RA, Horber DH, Ottiger C, Schott H (1995) Preclinical properties ofN 4-hexadecyl-andN 4-octadecyl-1-β-D-arabinofuranosylcytosine in liposomal preparations. J Liposome Res 5:27–47
Thomson ABR, Schoeller C, Keelan M, Smith L, Clandinin MT (1993) Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond. Can J Physiol Pharmacol 71:531–555
Tsuruo T, Tsukagoshi S, Sakurai Y (1980),N 4-Palmitoyl-andN 4-stearoyl-1-β-D-arabinofuranosylcytosine as new antitumor agent. In: Grassi JD (ed) Current chemotherapy and infectious disease. American Society of Microbiology, Washington, DC, pp 1591–1593
Ueda T, Kamiya K, Urasaki Y, Wataya S, Kawai Y, Tsutani H, Sugiyama M, Nakamura T (1994) Clinical pharmacology of 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate, an orally administred long-acting derivative of low-dose 1-β-D-arabinofuranosylcytosine. Cancer Res 54:109–113
Wempen I, Miller N, Falco EA, Fox JJ (1968) Nucleosides. XLVII. Synthesis of someN 4-substituted derivatives of 1-β-D-arabinofuranosyl cytosine and-5-fluorocytosine. J Med Chem 11:144–148
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schwendener, R.A., Horber, D.H., Odermatt, B. et al. Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations ofN 4-alkyl derivatives of 1-β-d-arabinofuranosylcytosine. J Cancer Res Clin Oncol 122, 102–108 (1996). https://doi.org/10.1007/BF01226267
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01226267